Tag: ASTE
Risk-Reducing Mastectomy Cost-Effective With Breast Cancer Risk ≥35 Percent
Risk-reducing mastectomy cost-effective for women aged 30 to 55 years with lifetime breast cancer risk of 35 percent or higher
BRCA Mutations Linked to Breast Implant Anaplastic Large Cell Lymphoma
Age-adjusted rate of developing BIA-ALCL 16 times higher for women with mutations versus without
Odds of Advanced Cancer, Breast Cancer Death Lower in Screen-Detected Disease
Risk for breast cancer-related death and odds of mastectomy were higher for symptom-detected cancer